Status:

COMPLETED

Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Lead Sponsor:

Protalix

Conditions:

Gaucher Disease

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD)leading to reduced activity of the lysosomal enzyme glucocerebrosidase ...

Eligibility Criteria

Inclusion

  • Healthy male or female between 18 and 45 years of age.
  • Female subjects must agree to use a medically acceptable method of contraception at all times during the study and must have a negative serum pregnancy test at baseline and during the study period.
  • Females of child-bearing potential must be non-pregnant and not lactating and using adequate birth control such as oral contraceptives.
  • Negative laboratory tests for HIV, HBsAg or HCV.
  • Naive to any previous recombinant protein therapy.
  • Provide written informed consent.
  • Have the ability to understand the requirements of the study and to comply with the study protocol and dosing regimen.

Exclusion

  • Have clinical evidence of any active significant disease that could potentially compromise the ability of the investigator to evaluate or interpret the effects of the study treatment on safety assessment and thus increase the risk to the subject to unacceptable levels.
  • Are pregnant or nursing.
  • Presence of any acute or chronic diseases.
  • Have a history of any allergies.
  • Have been exposed to long-term steroid treatment.
  • Had a minor operation in the last 6 months.
  • Have ever been exposed to any previous recombinant protein therapy.
  • Have received immuno-suppressive treatment.
  • Have a positive HIV, HBsAG and HCV laboratory result.
  • Use any medication other than vitamins or oral contraceptives (for female).
  • Have participated in another clinical trial during the previous 3 months
  • Have history of alcohol or drug abuse.
  • Are considered by the Investigator to be unsuitable candidate for this study.

Key Trial Info

Start Date :

November 1 2005

Trial Type :

INTERVENTIONAL

End Date :

January 1 2006

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT00258778

Start Date

November 1 2005

End Date

January 1 2006

Last Update

December 5 2006

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.